ProKidney Stock Forecast
NASDAQ: PROKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 10:10 AM ET
PROK analyst consensus
Consensus (7 analysts)
none
Avg. price target
$6.25+296.78%
- Strong buy 0
- Buy 4
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering ProKidney (2026-10-08), 4 rate the stock a buy or strong buy, 2 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $6.25, with a high estimate of $12.00 and a low estimate of $1.00. The average target implies upside of 296.8% from the current price of $1.58.
The spread between the highest and lowest targets is 1100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PROK.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 57% |
| Hold | 2 | 29% |
| Sell | 0 | 0% |
| Strong sell | 1 | 14% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.00 | -36.52% |
| Average target | $6.25 | +296.78% |
| High target | $12.00 | +661.81% |